Literature DB >> 15961768

Cyclin D1 in breast cancer pathogenesis.

Andrew Arnold1, Alexandros Papanikolaou.   

Abstract

Taking a perspective on available evidence that emphasizes relevance to human disease, cyclin D1 is solidly established as an oncogene with an important pathogenetic role in breast cancer and other human tumors. However, the precise cellular mechanisms through which aberrant cyclin D1 expression drives human neoplasia are less well established. Indeed, emerging evidence suggests that cyclin D1 might act, predominantly or at least in part, through pathways that do not involve its widely accepted function as a cell cycle regulator. Although therapeutic exploitation of the role of cyclin D1 as a molecular driver of breast cancer carries great promise, it is also suggested that direct targeting of the cyclin D1 gene or gene products may prove more successful than approaches that rely on arguably incomplete knowledge of the oncogenic mechanisms of cyclin D1.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15961768     DOI: 10.1200/JCO.2005.05.064

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  153 in total

Review 1.  Molecular biology of breast cancer.

Authors:  Miguel Martín
Journal:  Clin Transl Oncol       Date:  2006-01       Impact factor: 3.405

2.  Cyclin D1/cyclin-dependent kinase 4 interacts with filamin A and affects the migration and invasion potential of breast cancer cells.

Authors:  Zhijiu Zhong; Wen-Shuz Yeow; Chunhua Zou; Richard Wassell; Chenguang Wang; Richard G Pestell; Judy N Quong; Andrew A Quong
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

3.  Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment.

Authors:  Agnieszka K Witkiewicz; Dayana B Rivadeneira; Adam Ertel; Jessica Kline; Terry Hyslop; Gordon F Schwartz; Paolo Fortina; Erik S Knudsen
Journal:  Am J Pathol       Date:  2011-07-12       Impact factor: 4.307

4.  Crystal structure of human CDK4 in complex with a D-type cyclin.

Authors:  Philip J Day; Anne Cleasby; Ian J Tickle; Marc O'Reilly; Joe E Coyle; Finn P Holding; Rachel L McMenamin; Jeff Yon; Rajiv Chopra; Christoph Lengauer; Harren Jhoti
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

5.  ANCCA, an estrogen-regulated AAA+ ATPase coactivator for ERalpha, is required for coregulator occupancy and chromatin modification.

Authors:  June X Zou; Alexey S Revenko; Li B Li; Abigael T Gemo; Hong-Wu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-12       Impact factor: 11.205

Review 6.  Cyclin D1, cancer progression, and opportunities in cancer treatment.

Authors:  Shuo Qie; J Alan Diehl
Journal:  J Mol Med (Berl)       Date:  2016-10-02       Impact factor: 4.599

7.  Mutational analysis of progesterone receptor functional domains in stable cell lines delineates sets of genes regulated by different mechanisms.

Authors:  Ignacio Quiles; Lluís Millán-Ariño; Alicia Subtil-Rodríguez; Belén Miñana; Nora Spinedi; Cecilia Ballaré; Miguel Beato; Albert Jordan
Journal:  Mol Endocrinol       Date:  2009-03-19

Review 8.  Tailoring to RB: tumour suppressor status and therapeutic response.

Authors:  Erik S Knudsen; Karen E Knudsen
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

9.  p18Ink4c and p53 Act as tumor suppressors in cyclin D1-driven primitive neuroectodermal tumor.

Authors:  Raya Saab; Carlos Rodriguez-Galindo; Kelly Matmati; Jerold E Rehg; Shannon H Baumer; Joseph D Khoury; Catherine Billups; Geoffrey Neale; Kathleen J Helton; Stephen X Skapek
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

10.  FISH is more sensitive than Southern analysis at identifying increased levels of cyclin D1 gene amplified in breast cancer cell lines.

Authors:  Nie Dongsong; Jian Y Zhou
Journal:  Mol Biol Rep       Date:  2009-12-05       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.